Leukaemia group backs Curis' dual Pi3K/HDAC inhibitor with $4 million
This article was originally published in Scrip
Curis will be getting a boost of up to $4 million in funding from the Leukemia & Lymphoma Society (LLS), which has agreed to support 50% of the direct development costs for CUDC-907, a oral small molecule dual Pi3K and HDAC inhibitor under investigation as a treatment for patients with B-cell lymphoma and multiple myeloma.
You may also be interested in...
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.
Hillary Clinton's plan to rein in high prices of older medicines, which includes creating a federal panel that has authority to impose fines, may grab headlines, but some analysts think it's unlikely to get very far in a divided Washington.